Comprehensive Stock Comparison
Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Vertex Pharmaceuticals Incorporated (VRTX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | ALNY | 65.2% revenue growth vs VRTX's 8.9% |
| Value | VRTX | Lower P/E (25.7x vs 49.0x) |
| Quality / Margins | VRTX | 31.3% net margin vs ALNY's 8.4% |
| Stability / Safety | VRTX | Beta 0.44 vs ALNY's 0.88, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | ALNY | +34.9% vs VRTX's +3.6% |
| Efficiency (ROA) | VRTX | 14.8% ROA vs ALNY's 6.3%, ROIC 22.8% vs 19.1% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Alnylam Pharmaceuticals is a biopharmaceutical company that develops and commercializes RNA interference (RNAi) therapeutics for rare genetic diseases. It generates revenue primarily from sales of its approved RNAi drugs — ONPATTRO, GIVLAARI, OXLUMO, and others — targeting conditions like hereditary transthyretin amyloidosis, acute hepatic porphyria, and primary hyperoxaluria. The company's key advantage is its pioneering RNAi technology platform and intellectual property estate, which creates a significant barrier to entry in the RNAi therapeutics space.
Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing transformative medicines for serious diseases, with its flagship franchise targeting cystic fibrosis. It generates nearly all its revenue from CF therapies — primarily Trikafta/Kaftrio — while building a pipeline in pain, kidney disease, and type 1 diabetes. Its moat stems from deep scientific expertise in CFTR biology and a dominant, near-monopoly position in the CF treatment market.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
VRTX leads in 4 of 6 categories — strongest in Financial Metrics and Valuation Metrics. 1 category is tied.
Financial Metrics (TTM)
VRTX is the larger business by revenue, generating $11.7B annually — 3.2x ALNY's $3.7B. VRTX is the more profitable business, keeping 31.3% of every revenue dollar as net income compared to ALNY's 8.4%. On growth, ALNY holds the edge at +84.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ALNYAlnylam Pharmaceu… | VRTXVertex Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $3.7B | $11.7B |
| EBITDAEarnings before interest/tax | $557M | $4.2B |
| Net IncomeAfter-tax profit | $314M | $3.7B |
| Free Cash FlowCash after capex | $465M | $3.3B |
| Gross MarginGross profit ÷ Revenue | +81.8% | +86.3% |
| Operating MarginEBIT ÷ Revenue | +13.5% | +34.1% |
| Net MarginNet income ÷ Revenue | +8.4% | +31.3% |
| FCF MarginFCF ÷ Revenue | +12.5% | +28.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +84.9% | +11.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.1% | +4.7% |
Valuation Metrics
At 32.4x trailing earnings, VRTX trades at a 77% valuation discount to ALNY's 142.9x P/E. On an enterprise value basis, VRTX's 26.6x EV/EBITDA is more attractive than ALNY's 81.4x.
| Metric | ALNYAlnylam Pharmaceu… | VRTXVertex Pharmaceut… |
|---|---|---|
| Market CapShares × price | $44.1B | $126.2B |
| Enterprise ValueMkt cap + debt − cash | $45.4B | $124.8B |
| Trailing P/EPrice ÷ TTM EPS | 142.88x | 32.43x |
| Forward P/EPrice ÷ next-FY EPS est. | 48.96x | 25.66x |
| PEG RatioP/E ÷ EPS growth rate | — | 3.91x |
| EV / EBITDAEnterprise value multiple | 81.44x | 26.63x |
| Price / SalesMarket cap ÷ Revenue | 11.87x | 10.52x |
| Price / BookPrice ÷ Book value/share | 56.82x | 6.87x |
| Price / FCFMarket cap ÷ FCF | 94.70x | 39.51x |
Profitability & Efficiency
ALNY delivers a 39.8% return on equity — every $100 of shareholder capital generates $40 in annual profit, vs $21 for VRTX. VRTX carries lower financial leverage with a 0.20x debt-to-equity ratio, signaling a more conservative balance sheet compared to ALNY's 3.76x. On the Piotroski fundamental quality scale (0–9), ALNY scores 6/9 vs VRTX's 5/9, reflecting solid financial health.
| Metric | ALNYAlnylam Pharmaceu… | VRTXVertex Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | +39.8% | +21.2% |
| ROA (TTM)Return on assets | +6.3% | +14.8% |
| ROICReturn on invested capital | +19.1% | +22.8% |
| ROCEReturn on capital employed | +15.3% | +23.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 |
| Debt / EquityFinancial leverage | 3.76x | 0.20x |
| Net DebtTotal debt minus cash | $1.3B | $3.7B |
| Cash & Equiv.Liquid assets | $1.7B | $5.1B |
| Total DebtShort + long-term debt | $3.0B | $3.7B |
| Interest CoverageEBIT ÷ Interest expense | 7.20x | 348.55x |
Total Returns (with DRIP)
A $10,000 investment in VRTX five years ago would be worth $23,616 today (with dividends reinvested), compared to $22,381 for ALNY. Over the past 12 months, ALNY leads with a +34.9% total return vs VRTX's +3.6%. The 3-year compound annual growth rate (CAGR) favors ALNY at 20.3% vs VRTX's 19.6% — a key indicator of consistent wealth creation.
| Metric | ALNYAlnylam Pharmaceu… | VRTXVertex Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -16.8% | +9.9% |
| 1-Year ReturnPast 12 months | +34.9% | +3.6% |
| 3-Year ReturnCumulative with dividends | +73.9% | +71.1% |
| 5-Year ReturnCumulative with dividends | +123.8% | +136.2% |
| 10-Year ReturnCumulative with dividends | +468.4% | +481.2% |
| CAGR (3Y)Annualised 3-year return | +20.3% | +19.6% |
Risk & Volatility
VRTX is the less volatile stock with a 0.44 beta — it tends to amplify market swings less than ALNY's 0.88 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VRTX currently trades 95.6% from its 52-week high vs ALNY's 67.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ALNYAlnylam Pharmaceu… | VRTXVertex Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.88x | 0.44x |
| 52-Week HighHighest price in past year | $495.55 | $519.68 |
| 52-Week LowLowest price in past year | $205.87 | $362.50 |
| % of 52W HighCurrent price vs 52-week peak | +67.2% | +95.6% |
| RSI (14)Momentum oscillator 0–100 | 43.8 | 54.6 |
| Avg Volume (50D)Average daily shares traded | 1.2M | 1.2M |
Analyst Outlook
Wall Street rates ALNY as "Buy" and VRTX as "Buy". Consensus price targets imply 38.5% upside for ALNY (target: $461) vs 9.7% for VRTX (target: $545).
| Metric | ALNYAlnylam Pharmaceu… | VRTXVertex Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $461.06 | $545.08 |
| # AnalystsCovering analysts | 51 | 55 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.6% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Alnylam Pharmaceuti… (ALNY) | 100 | 304.35 | +204.4% |
| Vertex Pharmaceutic… (VRTX) | 100 | 206.79 | +106.8% |
Vertex Pharmaceutic… (VRTX) returned +136% over 5 years vs Alnylam Pharmaceuti… (ALNY)'s +124%. A $10,000 investment in VRTX 5 years ago would be worth $23,616 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Alnylam Pharmaceuti… (ALNY) | $47M | $3.7B | +7775.4% |
| Vertex Pharmaceutic… (VRTX) | $1.7B | $12.0B | +605.1% |
Alnylam Pharmaceuticals, Inc.'s revenue grew from $47M (2016) to $3.7B (2025) — a 62.4% CAGR. Vertex Pharmaceuticals Incorporated's revenue grew from $1.7B (2016) to $12.0B (2025) — a 24.2% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Alnylam Pharmaceuti… (ALNY) | -8.7% | 8.4% | +197.1% |
| Vertex Pharmaceutic… (VRTX) | -6.6% | 32.9% | +600.4% |
Alnylam Pharmaceuticals, Inc.'s net margin went from -9% (2016) to 8% (2025). Vertex Pharmaceuticals Incorporated's net margin went from -7% (2016) to 33% (2025).
Chart 4P/E Ratio History — 8 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Vertex Pharmaceutic… (VRTX) | 144.1 | 29.6 | -79.5% |
Vertex Pharmaceuticals Incorporated has traded in a 21x–144x P/E range over 8 years; current trailing P/E is ~32x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Alnylam Pharmaceuti… (ALNY) | -4.79 | 2.33 | +148.6% |
| Vertex Pharmaceutic… (VRTX) | -0.46 | 15.32 | +3430.4% |
Alnylam Pharmaceuticals, Inc.'s EPS grew from $-4.79 (2016) to $2.33 (2025). Vertex Pharmaceuticals Incorporated's EPS grew from $-0.46 (2016) to $15.32 (2025).
Chart 6Free Cash Flow — 5 Years
Alnylam Pharmaceuticals, Inc. generated $465M FCF in 2025 (+165% vs 2021). Vertex Pharmaceuticals Incorporated generated $3B FCF in 2025 (+33% vs 2021).
ALNY vs VRTX: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is ALNY or VRTX a better buy right now?
Vertex Pharmaceuticals Incorporated (VRTX) offers the better valuation at 32.4x trailing P/E (25.7x forward), making it the more compelling value choice. Analysts rate Alnylam Pharmaceuticals, Inc. (ALNY) a "Buy" — based on 51 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ALNY or VRTX?
On trailing P/E, Vertex Pharmaceuticals Incorporated (VRTX) is the cheapest at 32.4x versus Alnylam Pharmaceuticals, Inc. at 142.9x. On forward P/E, Vertex Pharmaceuticals Incorporated is actually cheaper at 25.7x.
03Which is the better long-term investment — ALNY or VRTX?
Over the past 5 years, Vertex Pharmaceuticals Incorporated (VRTX) delivered a total return of +136.2%, compared to +123.8% for Alnylam Pharmaceuticals, Inc. (ALNY). A $10,000 investment in VRTX five years ago would be worth approximately $24K today (assuming dividends reinvested). Over 10 years, the gap is even starker: VRTX returned +481.2% versus ALNY's +468.4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ALNY or VRTX?
By beta (market sensitivity over 5 years), Vertex Pharmaceuticals Incorporated (VRTX) is the lower-risk stock at 0.44β versus Alnylam Pharmaceuticals, Inc.'s 0.88β — meaning ALNY is approximately 99% more volatile than VRTX relative to the S&P 500. On balance sheet safety, Vertex Pharmaceuticals Incorporated (VRTX) carries a lower debt/equity ratio of 20% versus 4% for Alnylam Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — ALNY or VRTX?
Vertex Pharmaceuticals Incorporated (VRTX) is the more profitable company, earning 32.9% net margin versus 8.4% for Alnylam Pharmaceuticals, Inc. — meaning it keeps 32.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39.1% versus 13.5% for ALNY. At the gross margin level — before operating expenses — VRTX leads at 86.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ALNY or VRTX more undervalued right now?
On forward earnings alone, Vertex Pharmaceuticals Incorporated (VRTX) trades at 25.7x forward P/E versus 49.0x for Alnylam Pharmaceuticals, Inc. — 23.3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALNY: 38.5% to $461.06.
07Which pays a better dividend — ALNY or VRTX?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is ALNY or VRTX better for a retirement portfolio?
For long-horizon retirement investors, Vertex Pharmaceuticals Incorporated (VRTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.44), +481.2% 10Y return). Both have compounded well over 10 years (VRTX: +481.2%, ALNY: +468.4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ALNY and VRTX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.